WO2014203198A3 - Compositions and methods for the treatment of neurological diseases and renal complications - Google Patents

Compositions and methods for the treatment of neurological diseases and renal complications Download PDF

Info

Publication number
WO2014203198A3
WO2014203198A3 PCT/IB2014/062442 IB2014062442W WO2014203198A3 WO 2014203198 A3 WO2014203198 A3 WO 2014203198A3 IB 2014062442 W IB2014062442 W IB 2014062442W WO 2014203198 A3 WO2014203198 A3 WO 2014203198A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
compositions
renal
methods
neurological diseases
Prior art date
Application number
PCT/IB2014/062442
Other languages
French (fr)
Other versions
WO2014203198A2 (en
Inventor
Mahesh Kandula
Original Assignee
Mahesh Kandula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahesh Kandula filed Critical Mahesh Kandula
Publication of WO2014203198A2 publication Critical patent/WO2014203198A2/en
Publication of WO2014203198A3 publication Critical patent/WO2014203198A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups

Abstract

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological diseases and renal complications may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of renal transplantation, preservation of renal function in rhabdomyolysis secondary to crush injuries and compartment syndrome, Bowel preparation before colorectal surgery, colonoscopy, and barium enemas, promotion of urinary excretion of toxic material, chronic Pain, diabetic neuropathy, seizures, Creutzfeld- Jacob disease, multiple sclerosis, Parkinson's, Obesity, bipolar depression, partial-onset seizures and spasm.
PCT/IB2014/062442 2013-06-22 2014-06-19 Compositions and methods for the treatment of neurological diseases and renal complications WO2014203198A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2711/CHE/2013 2013-06-22
IN2711CH2013 2013-06-22

Publications (2)

Publication Number Publication Date
WO2014203198A2 WO2014203198A2 (en) 2014-12-24
WO2014203198A3 true WO2014203198A3 (en) 2015-04-02

Family

ID=52105417

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/062442 WO2014203198A2 (en) 2013-06-22 2014-06-19 Compositions and methods for the treatment of neurological diseases and renal complications

Country Status (1)

Country Link
WO (1) WO2014203198A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3890713A4 (en) * 2018-12-05 2023-01-04 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University L-dopa and/or dopa decarboxylse inhibitors conjugated to sugar for the treatment of dopamine-responsive disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008101310A1 (en) * 2007-02-20 2008-08-28 Multi Formulations Ltd. Creatine-fatty acids
WO2008101309A1 (en) * 2007-02-20 2008-08-28 Multi Formulations Ltd. Creatine-fatty acids
WO2012149352A1 (en) * 2011-04-29 2012-11-01 Catabasis Pharmaceuticals, Inc. Fatty acid guanidine and salicylate guanidine derivatives and their uses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008101310A1 (en) * 2007-02-20 2008-08-28 Multi Formulations Ltd. Creatine-fatty acids
WO2008101309A1 (en) * 2007-02-20 2008-08-28 Multi Formulations Ltd. Creatine-fatty acids
WO2012149352A1 (en) * 2011-04-29 2012-11-01 Catabasis Pharmaceuticals, Inc. Fatty acid guanidine and salicylate guanidine derivatives and their uses

Also Published As

Publication number Publication date
WO2014203198A2 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
WO2009039397A3 (en) Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer
WO2015017813A3 (en) Inhibitors of the farnesoid x receptor and uses in medicine
WO2007133637A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2008040548A3 (en) Treatment for non-alcoholic-steatohepatitis
WO2009029622A3 (en) Antiviral drugs for treatment of arenavirus infection
WO2013175377A3 (en) Compositions and methods for treatment of mucositis
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2013123215A3 (en) Antiviral drugs for treatment of arenavirus infection
WO2014174524A8 (en) A novel composition for nonalcoholic fatty liver disease (nafld)
MD4436B1 (en) Compounds for the treatment of addiction
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
EA201171088A1 (en) TREATMENT OF DISKINESIA IN DIFFERENT DISORDERS
WO2008079610A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
EA201070783A1 (en) 1,2,4-OXADISOL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
WO2016127168A3 (en) Mebendazole polymorph for treatment and prevention of tumors
EP2215054B8 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
CL2008000554A1 (en) COMPOUNDS DERIVED FROM REPLACED DIAMINOPIRIMIDINE; METHOD OF PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND FOR THE TREATMENT OF AN URINARY TRACT DISEASE, A PAINFUL PATHOLOGICAL STATE, A DISORDER RES
WO2014087307A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
WO2010046273A3 (en) Pyrimidinyl pyridone inhibitors of jnk
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
WO2014203198A3 (en) Compositions and methods for the treatment of neurological diseases and renal complications
WO2014091384A3 (en) Compositions and methods for the treatment of mucositis

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14814638

Country of ref document: EP

Kind code of ref document: A2